Panel Discussion: Building a Robust Raw Material Strategy for Advanced Therapies
- Establishing a phase-appropriate raw material strategy that supports both early development flexibility and late-stage regulatory expectations
- Navigating evolving regulatory expectations for raw materials
- Evaluating supplier strategies, including sole vs dual sourcing, to mitigate supply chain risk while maintaining product comparability and regulatory compliance